Intro Study Designs-AB
Intro Study Designs-AB
Global Health
Analytic
Descriptive
(association)
•Case report/series
•Cross sectional/Survey Observational
Experimental
•Cross sectional/Survey
•Randomized
•Ecological
controlled trials
•Case-control
•Cohort studies
Quasi-Experimental
•Before-after
•Time-series analysis
(looking forward)
time
Study begins here
TIMEFRAME OF STUDIES
(looking back)
time
STRENGHTS LIMITATIONS
• Useful for hypothesis • Cannot study cause and
generation effect relationships
• Informative for very • Cannot assess disease
rare disease with few frequency
established risk factors
• Characterizes averages
for disorder
¿What is the prevalence of HIV+
among adults in my health district?
CROSS-SECTIONAL STUDIES
time
60
50
40
30
20
10.8
10
0
Yes No
Ever been diagnosed with diabetes?
source of potential bias:
non-response
Sample
Population
ECOLOGIC STUDIES
STRENGHTS LIMITATIONS
• Quick, simple, inexpensive
• Ecologic Fallacy
• Good for generating hypotheses
when disease is of unknown
etiology
• Some exposures may not vary
within a given group, and some
variables are only
defined/measured for groups
• Sometimes question is about
group differences, not individual
differences
• Brings back Context to
epidemiologic discussion
Do HIV+ individuals have a higher risk of TB
than HIV- individuals?
COHORT DESIGN
PROSPECTIVE RETROSPECTIVE
STRENGHTS LIMITATIONS
• Exposure status • Expensive and time-
determined before disease consuming
detection • Inefficient for rare diseases
• Subjects selected before or diseases with long
disease detection latency
• Can study several • Loss to follow-up
outcomes for each
exposure
CASE-CONTROL DESIGN
STRENGHTS LIMITATIONS
• Less expensive and time • Exposure measurements
consuming than prospective taken after disease
cohorts occurrence
• Efficient for studying rare • Disease status can influence
diseases selection of subjects
¿Does that risk change if I give them ATB
compared to no treatment?
EXPERIMENTAL STUDIES: RANDOMIZED CONTROL TRIAL
Randomization
STRENGHTS LIMITATIONS
• Confounding control • Duration of trials
• Prospective measurement – Expense